ORY.MC BME
Oryzon Genomics S.A.
1W: +0.0%
1M: -2.9%
3M: -7.8%
YTD: -13.1%
1Y: +2.2%
3Y: +33.2%
5Y: -15.7%
€2.73 ($3.08)
-0.02 (-0.80%)
Weekly Expected Move ±2.5%
€3
€3
€3
€3
€3
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
-$2M
+58.6% ▲
Capital Expenditures
$59K
+99.2% ▲
5Y CAGR: -63.5%
Free Cash Flow
-$2M
+82.0% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$23M
+442.5% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$5M | -$2M | -$3M | -$4M | -$3M |
| Depreciation & Amort. | $144K | $179K | $153K | $148K | $134K |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | $923K | $384K | $365K | -$147K | $494K |
| Other Non-Cash Items | -$7K | $60K | $2M | -$2M | -$378K |
| Operating Cash Flow | -$4M | -$2M | -$575K | -$6M | -$2M |
| — Investing Activities — | |||||
| Capital Expenditures | -$12M | -$14M | -$15M | -$8M | -$11M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | -$6K | -$799 | -$1K | -$102K | $0 |
| Investment Sales | $43K | $147 | $272 | $0 | $2K |
| Other Investing | $0 | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$12M | -$14M | -$15M | -$8M | -$11M |
| — Financing Activities — | |||||
| Net Debt Issuance | $4M | $10M | $8M | -$2M | $3M |
| Stock Repurchased | $0 | -$1M | -$2M | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $0 | $68K | -$80K | $8M | $4M |
| Financing Cash Flow | $4M | $9M | $6M | $7M | $36M |
| Net Change in Cash | -$11M | -$7M | -$9M | -$7M | $23M |
| Cash End of Period | $29M | $21M | $12M | $6M | $28M |
| Free Cash Flow | -$15M | -$16M | -$15M | -$13M | -$2M |